Caprock Group, Inc. Protagonist Therapeutics, Inc Transaction History
Caprock Group, Inc.
- $3 Billion
- Q4 2024
A detailed history of Caprock Group, Inc. transactions in Protagonist Therapeutics, Inc stock. As of the latest transaction made, Caprock Group, Inc. holds 5,802 shares of PTGX stock, worth $218,039. This represents 0.01% of its overall portfolio holdings.
Number of Shares
5,802Holding current value
$218,039% of portfolio
0.01%Shares
1 transactions
Others Institutions Holding PTGX
# of Institutions
245Shares Held
56.8MCall Options Held
71.7KPut Options Held
114K-
Farallon Capital Management LLC San Francisco, CA5.86MShares$220 Million1.32% of portfolio
-
Black Rock Inc. New York, NY5.76MShares$216 Million0.0% of portfolio
-
Rtw Investments, LP New York, NY5.43MShares$204 Million3.89% of portfolio
-
Vanguard Group Inc Valley Forge, PA4.22MShares$158 Million0.0% of portfolio
-
State Street Corp Boston, MA3.18MShares$120 Million0.01% of portfolio
About Protagonist Therapeutics, Inc
- Ticker PTGX
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 49,084,100
- Market Cap $1.84B
- Description
- Protagonist Therapeutics, Inc., a biopharmaceutical company, discovers and develops peptide-based therapeutic drugs to address hematology and blood disorders, and inflammatory and immunomodulatory diseases. It is developing rusfertide (PTG-300), an injectable hepcidin mimetic that is in Phase II clinical trials for the treatment of patients with...